Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis

Roberta Elisa Rossi, Clorinda Ciafardini, Valentina Sciola, Dario Conte, Sara Massironi

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: Little is known about chromogranin A (CgA) during follow-up of gastroenteropancreatic neuroendocrine neoplasms. We hypothesized that serial CgA monitoring might be useful for the assessment of tumor progression, and we performed a systematic review of the literature and meta-analysis.

METHODS: A bibliographical search was performed in PubMed using "chromogranin A" and "neuroendocrine tumors" and "follow-up" and "biomarker" to identify all pertinent articles published in the last 10 years.

RESULTS: Eight studies were included in current meta-analysis. Chromogranin A as a follow-up marker shows sensitivity between 46% and 100% and specificity between 68% and 90%. The meta-analysis results showed an overall accuracy of 84% (95% confidence interval [CI], 81-86.6), a cumulative sensitivity of 74.6% (95% CI, 61.9-85.4), and a cumulative specificity of 84.7% (95% CI, 81.3-87.7). These data indicate that circulating CgA has a better overall accuracy in the follow-up setting; it can be used to rule the diagnosis of recurrence/progression in, rather than to rule it out.

CONCLUSIONS: Chromogranin A is more reliable when used to monitor disease progression and response to treatment and for the early detection of recurrence after treatment rather than in the diagnostic setting. It is more sensible to use this marker in those cases where the initial values were impaired.

Original languageEnglish
Pages (from-to)1249-1255
Number of pages7
JournalPancreas
Volume47
Issue number10
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Chromogranin A
Meta-Analysis
Neoplasms
Confidence Intervals
Recurrence
Neuroendocrine Tumors
PubMed
Disease Progression
Biomarkers

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms : Is It Really Game Over? A Systematic Review and Meta-analysis. / Rossi, Roberta Elisa; Ciafardini, Clorinda; Sciola, Valentina; Conte, Dario; Massironi, Sara.

In: Pancreas, Vol. 47, No. 10, 01.11.2018, p. 1249-1255.

Research output: Contribution to journalArticle

Rossi, Roberta Elisa ; Ciafardini, Clorinda ; Sciola, Valentina ; Conte, Dario ; Massironi, Sara. / Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms : Is It Really Game Over? A Systematic Review and Meta-analysis. In: Pancreas. 2018 ; Vol. 47, No. 10. pp. 1249-1255.
@article{660f67d95d15425899ae8d6a4534dbf8,
title = "Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis",
abstract = "OBJECTIVES: Little is known about chromogranin A (CgA) during follow-up of gastroenteropancreatic neuroendocrine neoplasms. We hypothesized that serial CgA monitoring might be useful for the assessment of tumor progression, and we performed a systematic review of the literature and meta-analysis.METHODS: A bibliographical search was performed in PubMed using {"}chromogranin A{"} and {"}neuroendocrine tumors{"} and {"}follow-up{"} and {"}biomarker{"} to identify all pertinent articles published in the last 10 years.RESULTS: Eight studies were included in current meta-analysis. Chromogranin A as a follow-up marker shows sensitivity between 46{\%} and 100{\%} and specificity between 68{\%} and 90{\%}. The meta-analysis results showed an overall accuracy of 84{\%} (95{\%} confidence interval [CI], 81-86.6), a cumulative sensitivity of 74.6{\%} (95{\%} CI, 61.9-85.4), and a cumulative specificity of 84.7{\%} (95{\%} CI, 81.3-87.7). These data indicate that circulating CgA has a better overall accuracy in the follow-up setting; it can be used to rule the diagnosis of recurrence/progression in, rather than to rule it out.CONCLUSIONS: Chromogranin A is more reliable when used to monitor disease progression and response to treatment and for the early detection of recurrence after treatment rather than in the diagnostic setting. It is more sensible to use this marker in those cases where the initial values were impaired.",
author = "Rossi, {Roberta Elisa} and Clorinda Ciafardini and Valentina Sciola and Dario Conte and Sara Massironi",
year = "2018",
month = "11",
day = "1",
doi = "10.1097/MPA.0000000000001184",
language = "English",
volume = "47",
pages = "1249--1255",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms

T2 - Is It Really Game Over? A Systematic Review and Meta-analysis

AU - Rossi, Roberta Elisa

AU - Ciafardini, Clorinda

AU - Sciola, Valentina

AU - Conte, Dario

AU - Massironi, Sara

PY - 2018/11/1

Y1 - 2018/11/1

N2 - OBJECTIVES: Little is known about chromogranin A (CgA) during follow-up of gastroenteropancreatic neuroendocrine neoplasms. We hypothesized that serial CgA monitoring might be useful for the assessment of tumor progression, and we performed a systematic review of the literature and meta-analysis.METHODS: A bibliographical search was performed in PubMed using "chromogranin A" and "neuroendocrine tumors" and "follow-up" and "biomarker" to identify all pertinent articles published in the last 10 years.RESULTS: Eight studies were included in current meta-analysis. Chromogranin A as a follow-up marker shows sensitivity between 46% and 100% and specificity between 68% and 90%. The meta-analysis results showed an overall accuracy of 84% (95% confidence interval [CI], 81-86.6), a cumulative sensitivity of 74.6% (95% CI, 61.9-85.4), and a cumulative specificity of 84.7% (95% CI, 81.3-87.7). These data indicate that circulating CgA has a better overall accuracy in the follow-up setting; it can be used to rule the diagnosis of recurrence/progression in, rather than to rule it out.CONCLUSIONS: Chromogranin A is more reliable when used to monitor disease progression and response to treatment and for the early detection of recurrence after treatment rather than in the diagnostic setting. It is more sensible to use this marker in those cases where the initial values were impaired.

AB - OBJECTIVES: Little is known about chromogranin A (CgA) during follow-up of gastroenteropancreatic neuroendocrine neoplasms. We hypothesized that serial CgA monitoring might be useful for the assessment of tumor progression, and we performed a systematic review of the literature and meta-analysis.METHODS: A bibliographical search was performed in PubMed using "chromogranin A" and "neuroendocrine tumors" and "follow-up" and "biomarker" to identify all pertinent articles published in the last 10 years.RESULTS: Eight studies were included in current meta-analysis. Chromogranin A as a follow-up marker shows sensitivity between 46% and 100% and specificity between 68% and 90%. The meta-analysis results showed an overall accuracy of 84% (95% confidence interval [CI], 81-86.6), a cumulative sensitivity of 74.6% (95% CI, 61.9-85.4), and a cumulative specificity of 84.7% (95% CI, 81.3-87.7). These data indicate that circulating CgA has a better overall accuracy in the follow-up setting; it can be used to rule the diagnosis of recurrence/progression in, rather than to rule it out.CONCLUSIONS: Chromogranin A is more reliable when used to monitor disease progression and response to treatment and for the early detection of recurrence after treatment rather than in the diagnostic setting. It is more sensible to use this marker in those cases where the initial values were impaired.

UR - http://www.scopus.com/inward/record.url?scp=85055078917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055078917&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000001184

DO - 10.1097/MPA.0000000000001184

M3 - Article

C2 - 30325865

AN - SCOPUS:85055078917

VL - 47

SP - 1249

EP - 1255

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 10

ER -